TITLE

Role of the Glutamatergic System in Nicotine Dependence

AUTHOR(S)
Liechti, Matthias E.; Markou, Athina
PUB. DATE
July 2008
SOURCE
CNS Drugs;2008, Vol. 22 Issue 9, p705
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Preclinical research findings in laboratory animals indicate that the gluta-matergic system is critically involved in nicotine dependence. In animals, compounds that decrease glutamatergic neurotransmission, such as antagonists at postsynaptic NMDA receptors, antagonists at excitatory postsynaptic metabotropic glutamate (mGlu) 5 receptors, or agonists at inhibitory presynaptic mGlu2 and mGlu3 receptors, decreased nicotine self-administration or reinstatement of nicotine-seeking behaviour. These findings suggest that medications that decrease glutamatergic transmission overall may reduce the reinforcing effects of tobacco smoking and prevent relapse to tobacco smoking in humans. Furthermore, compounds that increase glutamate release, such as antagonists at mGlu2 and mGlu3 receptors, ameliorated reward deficits associated with nicotine withdrawal in animals, and thus may alleviate the depression-like symptoms associated with nicotine withdrawal in humans. Animal studies also showed that a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)/kainate receptors did not appear to be involved in mediating the primary reinforcing effects of nicotine but that they may be involved in the development of nicotine dependence and withdrawal. Taken together, the preclinical data indicate that different glutamatergic receptors are involved in the mediation of different aspects of nicotine dependence. These findings have implications for the discovery and development of new pharmacotherapies that target the glutamatergic system to aid in smoking cessation. At present, very few clinical studies have addressed the effects of glutamatergic compounds on cigarette smoking. Clinical studies involving compounds that have actions at ionotropic glutamate receptors are briefly discussed in this review and suggest the potential of glutamatergic compounds as pharmacotherapies to aid in smoking cessation. Medications that target mGlu receptors have recently been tested in human phase II trials for various indications; however, the potential of these mGlu compounds as medications for nicotine dependence remains to be evaluated in humans. The preclinical data evaluated in this review indicate that such clinical trials for smoking cessation with mGlu compounds are clearly warranted and may reveal novel treatments for nicotine dependence.
ACCESSION #
35282118

 

Related Articles

  • New medications for nicotine dependence treatment. Hurt, Richard D. // Nicotine & Tobacco Research;Sep1999 Supplement 2, Vol. 1, pS175 

    For several years, nicotine replacement therapy (nicotine gum, patches, and nasal spray) has been the mainstay for the treatment of nicotine dependence. The nicotine vapor inhaler is a new pharmacological adjunct shown to be effective in placebo-controlled trials. It delivers a vaporized form of...

  • Tobacco cessation pharmacotherapy use among First Nations persons residing within British Columbia. Wardman, A. E. Dennis; Khan, Nadia A. // Nicotine & Tobacco Research;Aug2004, Vol. 6 Issue 4, p689 

    The rate of tobacco use is higher among First Nations (FN) peoples than among other Canadians. Cessation pharmacotherapy agents reduce tobacco use, but the appropriateness and effectiveness of these agents among FN smokers are not entirely clear. Rates of tobacco cessation pharmacotherapy use...

  • Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Cornuz, J.; Gilbert, A.; Pinget, C.; McDonald, P.; Slama, K.; Salto, E.; Paccaud, F. // Tobacco Control;Jun2006, Vol. 15 Issue 3, p152 

    Objective: To estimate the incremental cost-effectiveness of the first-line pharmacotherapies (nicotine gum, patch, spray, inhaler, and bupropion) for smoking cessation across six Western countries-Canada, France, Spain, Switzerland, the United States, and the United Kingdom. Design and study...

  • An overview of pharmacological aids available to enhance smoking cessation. Al-Doghether, Mohammed H. // Asia Pacific Family Medicine;Jul2004, Vol. 3, p13 

    Tobacco dependence is a chronic condition that usually requires repeated intervention. Effective interventions exist that can produce long-term cessation at up to double the rate achieved by smokers without treatment. Because pharmacotherapies enhance the quit rates of most other cessation...

  • Pharmacotherapy. Williams, Jill M.; Hughes, John R. // Psychiatric Annals;Jul2003, Vol. 33 Issue 7, p457 

    The article reviews the use of pharmacotherapies for tobacco dependence treatment. The issues relevant to treatment of tobacco dependence in mental health and addictions populations. The pharmacotherapies include bupropion hydrochloride and nicotine replacement therapy. It explains that the...

  • Cost-effectiveness of bupropion, nortriptyline, and psychological intervention in smoking cessation. Hall, Sharon M.; Lightwood, James M.; Humfleet, Gary L.; Bostrom, Alan; Reus, Victor I.; Muñoz, Ricardo; Muñoz, Ricardo // Journal of Behavioral Health Services & Research;Oct-Dec2005, Vol. 32 Issue 4, p381 

    Sustained-release bupropion and nortriptyline have been shown to be efficacious in treating cigarette smoking. Psychological intervention is also recognized as efficacious. The cost and cost-effectiveness of the 2 drug therapies have not been estimated. It was hypothesized that nortriptyline...

  • Pharmacogenomics of Nicotine Dependence and Impact on Smoking Cessation. Johnstone, E. C.; Murphy, M.F. G. // Current Pharmacogenomics;Sep2007, Vol. 5 Issue 3, p178 

    Pharmacogenomic research into smoking behaviour and smoking cessation holds promise for understanding why people smoke and how we can better help people to quit. As smoking prevalence declines in the United States and Western Europe through social and clinical action, average level of tobacco...

  • JAMA PATIENT PAGE. Smoking Cessation. Brender, Erin // JAMA: Journal of the American Medical Association;12/8/2010, Vol. 304 Issue 22, p2548 

    The article offers information on smoking cessation. Identified benefits of smoking cessation include reduced risk of cancer, heart disease, stroke and early mortality. Suggested ways to quit smoking include being committed, getting help from a doctor and selecting a firm date to quit, among...

  • Varenicline and bupropion sustained-release combination therapy for smoking cessation. Ebbert, Jon O.; Croghan, Ivana T.; Sood, Amit; Schroeder, Darrell R.; Hays, J. Taylor; Hurt, Richard D. // Nicotine & Tobacco Research;Mar2009, Vol. 11 Issue 3, p234 

    Introduction:: Varenicline and bupropion sustained release (SR) are both safe and effective for the treatment of tobacco dependence and have different mechanisms of action. Combination pharmacotherapy with these agents may increase long-term smoking abstinence rates above what is observed with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics